Safi Biotherapeutics Inc.和DesiCorp Inc.启动合作以支持mRBCs的冻干工艺

Lyophilized (freeze-dried), manufactured red blood cells (mRBCs) represent a breakthrough solution for saving lives in pre-hospital, mass-casualty and far-forward military care environments

冻干（冷冻干燥）、制造的红细胞（mRBCs）代表了一种在院前、大规模伤亡和远前方军事护理环境中挽救生命的突破性解决方案。

CAMBRIDGE, Mass. and LOUISVILLE, Ky.

马萨诸塞州剑桥市和肯塔基州路易斯维尔市

,

，

March 31, 2026

2026年3月31日

/PRNewswire/ -- Safi Biotherapeutics Inc. and DesiCorp Inc. today announced a collaboration focused on freeze-drying Safi manufactured human red blood cells (mRBCs) to support the development of a highly portable, shelf-stable alternative to conventional donor blood products. The collaboration will allow each company to leverage its key competencies to expand access to life-saving care.

/PRNewswire/ -- Safi Biotherapeutics Inc. 和 DesiCorp Inc. 今天宣布了一项合作，专注于冷冻干燥 Safi 生产的人类红细胞 (mRBC)，以支持开发一种高度便携、货架稳定的传统供体血液替代品。此次合作将使各公司能够发挥其核心优势，扩大获得救命护理的机会。

Commercially available lyophilized (freeze-dried) mRBCs would represent a significant scientific breakthrough by expanding access, at scale, to life-saving transfusion outside traditional hospital settings, including battlefields, emergency vehicles and mass-casualty settings..

商业上可获得的冻干（冷冻干燥）mRBC将代表着一项重大的科学突破，它能够大规模地扩展在传统医院环境之外，包括战场、急救车辆和大规模伤亡环境中的救命输血机会。

Continue Reading

继续阅读

DesiCorp

德西公司

Safi Biotherapeutics Inc. is an expert in biomanufacturing stem-cell-derived, mRBCs as a dual-use product for civilian and military transfusion needs. DesiCorp Inc. is an expert in blood cell lyophilization, advanced packaging materials, solutions and manufacturing, to preserve sensitive compounds and extend shelf-life without refrigeration.

Safi Biotherapeutics Inc. 是生物制造干细胞衍生的红细胞（mRBCs）作为民用和军用输血需求的双重用途产品的专家。DesiCorp Inc. 专注于血细胞冻干、先进包装材料、解决方案及制造，以在无需冷藏的情况下保存敏感化合物并延长保质期。

Together, this partnership will combine Safi's expertise in biomanufacturing with DesiCorp's capabilities in lyophilization to accelerate access to life-saving transfusions..

双方将结合Safi在生物制造方面的专业知识和DesiCorp在冻干技术方面的能力，加快获得挽救生命的输血的机会。

'Early evidence suggests that mRBCs are well suited to freeze-drying, and the availability of a scalable, freeze-dried red blood cell supply would be paradigm-shifting in terms of transport, storage and stockpiling. DesiCorp, a leader in freeze-drying technology, brings the capabilities and expertise required to develop and optimize the lyophilization and reconstitution of Safi's mRBCs, making them the perfect partner for this critically important endeavor,' said Doug McConnell, Chief Executive Officer and Co-Founder of Safi Biotherapeutics Inc.

“早期证据表明，mRBCs 非常适合冻干，而可扩展的冻干红细胞供应在运输、存储和储备方面将带来颠覆性的变革。DesiCorp 作为冻干技术的领导者，具备开发和优化 Safi 的 mRBCs 冻干及再溶解所需的能力和专业知识，是这项至关重要任务的理想合作伙伴。”Safi Biotherapeutics Inc. 首席执行官兼联合创始人 Doug McConnell 表示。

'With the recent transfer of our initial clinical scale mRBC production system to our manufacturing partner, we are well-positioned to work with DesiCorp to develop and manufacture a freeze-dried formulation of Safi's mRBCs. We look forward to advancing this important work with DesiCorp.'.

“随着我们最初的临床规模 mRBC 生产系统最近转移到我们的制造合作伙伴，我们已准备好与 DesiCorp 合作开发和生产 Safi 的 mRBC 冻干配方。我们期待与 DesiCorp 推进这项重要工作。”

'Safi Biotherapeutics is the leader in allogeneic in vitro blood cell manufacturing, and we are committed to supporting their efforts to address critical shortages in military and civilian blood supply worldwide,' said Brett Janis, Ph.D., Chief Executive Officer and Co-Founder of DesiCorp Inc. 'Maintaining cellular structure and function through the cryopreservation and lyophilization process is critical to providing a high-quality freeze-dried blood product for use in settings where refrigeration isn't possible, such as battlefields and pre-hospital emergencies.

“Safi Biotherapeutics 是同种异体体外血细胞制造的领导者，我们致力于支持他们解决全球军事和民用血液供应严重短缺的问题，”DesiCorp Inc. 首席执行官兼联合创始人布雷特·贾尼斯 (Brett Janis) 博士说道。“通过冷冻保存和冻干过程维持细胞结构和功能，对于在无法冷藏的情况下（如战场和院前急救）提供高质量冻干血液产品至关重要。”

We look forward to working together to fulfill our combined mission of bringing life-saving blood to patients when and where it is needed most.'.

我们期待共同努力，履行我们的共同使命，将拯救生命的血液输送到最需要的时间和地点。

About Safi Biotherapeutics Inc.

关于沙菲生物治疗公司

Safi Biotherapeutics Inc. biomanufactures stem-cell-derived, human RBCs (mRBCs) to provide a highly characterized cell therapy product at an industrial scale and viable economics for civilian and military transfusion needs. Safi's manufacturing blueprint for mRBC production is the most advanced in the industry, and the company's readily addressable markets include chronic transfusion indications, such as sickle-cell disease (SCD), and acute transfusion settings, such as civilian and military hospitals during critical times of need.

Safi生物治疗公司生产干细胞衍生的人类红细胞（mRBC），以工业规模和可行的经济性提供高度特征化的细胞治疗产品，满足民用和军用输血需求。Safi的mRBC生产工艺蓝图是业内最先进的，其可迅速应对的市场包括慢性输血适应症（如镰状细胞病（SCD））以及急性输血场景（如在紧急需求时刻的民用和军用医院）。

Safi leadership, comprised of industry and cell therapy veterans from DARPA, Vertex Pharmaceuticals, Mass General Brigham, and Loughborough University in the United Kingdom, launched the company in 2020 as part of the U.S. Department of Defense .

Safi领导层由来自DARPA、Vertex Pharmaceuticals、Mass General Brigham以及英国拉夫堡大学的行业和细胞治疗资深人士组成，于2020年作为美国国防部的一部分创立了该公司。

On-Demand Blood

按需供血

program. Safi's mRBC product has been granted U.S. FDA Rare Pediatric Disease Designation and Orphan Drug Designation for use in chronic transfusion of patients with SCD.

Safi的mRBC产品已被授予美国FDA罕见儿科疾病认定和孤儿药认定，用于SCD患者的慢性输血。

For more information on Safi, visit:

有关Safi的更多信息，请访问：

https://safi.bio/

https://safi.bio/

or follow us on

或关注我们

LinkedIn

领英

.

。

About DesiCorp Inc.

关于DesiCorp公司

DesiCorp Inc. leverages its core competencies in life sciences, packaging solutions and advanced materials to eliminate medical shortages by extending product shelf life and simplifying logistics and storage. The Company's state-of-the-art technology allows for the preservation of sensitive compounds and therapeutics to extend shelf-life without refrigeration, eliminating the need for electrical infrastructure, mitigating costs associated with expiring products and enabling emergency medical services, rural clinics and remote field care providers to keep and utilize the same products used in general hospitals.

德赛公司利用其在生命科学、包装解决方案和先进材料方面的核心竞争力，通过延长产品保质期以及简化物流和存储来消除医疗短缺。公司最先进的技术能够在无需冷藏的情况下保存敏感化合物和治疗药物以延长保质期，从而无需电力基础设施，降低与产品过期相关的成本，并使紧急医疗服务、农村诊所和偏远地区的护理提供者能够保存并使用在综合医院中使用的相同产品。

For more information, visit .

有关更多信息，请访问 。

https://www.desicorpinc.com

https://www.desicorpinc.com

.

。

Safi Contact:

萨菲联系方式：

Doug McConnell

道格·麦康奈尔

[email protected]

电子邮件地址

DesiCorp Contact:

德西公司联系方式：

Brett Janis

布雷特·贾尼斯

[email protected]

电子邮件地址

Media Inquiries:

媒体询问：

David Rosen, Argot Partners

大卫·罗森，阿戈特合伙人

[email protected]

电子邮件地址

212-600-1902

212-600-1902

SOURCE Safi Biotherapeutics

来源：Safi Biotherapeutics

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示